Published in Cancer Weekly, July 30th, 2002
"While advanced lung cancer remains incurable, this study provides additional evidence that paclitaxel- and carboplatin-based regimens can prolong survival of patients with this disease," said John Hainsworth, MD, lead study author of a paper appearing in the Journal of Clinical Oncology and director of clinical research at the Sarah Cannon Cancer Center. "Survival beyond two years has been uncommon with previous treatments for advanced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.